Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

NCT02830932 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL: VXA-RSV-f Tablets (high dose)
OTHER: VXA Placebo Tablets
BIOLOGICAL: VXA-RSV-f Tablets (low dose)

Sponsor

Vaxart